The Future of Biological Therapies in COPD

Arch Bronconeumol (Engl Ed). 2018 Apr;54(4):185-186. doi: 10.1016/j.arbres.2017.11.004. Epub 2017 Dec 29.
[Article in English, Spanish]
No abstract available

Publication types

  • Editorial
  • Webcast

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antibody Specificity
  • Asthma / complications
  • Asthma / immunology
  • Asthma / therapy
  • Biological Therapy* / adverse effects
  • Biological Therapy* / methods
  • Cytokines / antagonists & inhibitors
  • Cytokines / immunology
  • Humans
  • I-kappa B Kinase / antagonists & inhibitors
  • Inflammation Mediators / antagonists & inhibitors
  • Inflammation Mediators / immunology
  • Microbiota / drug effects
  • Molecular Targeted Therapy*
  • NF-kappa B / antagonists & inhibitors
  • Pulmonary Disease, Chronic Obstructive / complications
  • Pulmonary Disease, Chronic Obstructive / immunology
  • Pulmonary Disease, Chronic Obstructive / microbiology
  • Pulmonary Disease, Chronic Obstructive / therapy*
  • Th1 Cells / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Cytokines
  • Inflammation Mediators
  • NF-kappa B
  • I-kappa B Kinase